ImmunoPrecise Antibodies Ltd.
IPA
$0.45
-$0.0139-3.00%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.06% | -0.95% | -9.86% | 14.70% | 20.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.06% | -0.95% | -9.86% | 14.70% | 20.11% |
| Cost of Revenue | -10.27% | -16.35% | -2.10% | 46.71% | 36.79% |
| Gross Profit | -2.09% | 15.72% | -17.88% | -7.15% | 7.69% |
| SG&A Expenses | -3.48% | 6.07% | -9.64% | 32.81% | -2.60% |
| Depreciation & Amortization | -16.51% | -14.25% | -30.29% | -46.87% | -31.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.20% | -0.60% | -1.52% | 20.52% | -2.11% |
| Operating Income | 6.45% | -0.16% | -10.31% | -32.79% | 27.19% |
| Income Before Tax | -574.25% | -17.42% | -21.43% | -218.65% | 24.89% |
| Income Tax Expenses | -268.02% | -176.57% | -82.16% | -1.11% | -846.50% |
| Earnings from Continuing Operations | -663.19% | -5.40% | -14.05% | -251.17% | 43.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -663.19% | -5.40% | -14.05% | -251.17% | 43.08% |
| EBIT | 6.45% | -0.16% | -10.31% | -32.79% | 27.19% |
| EBITDA | -12.46% | -31.37% | -41.33% | -74.62% | 29.89% |
| EPS Basic | -499.48% | 6.07% | -5.28% | -229.87% | 44.99% |
| Normalized Basic EPS | 27.58% | -4.62% | -12.15% | -34.77% | 27.40% |
| EPS Diluted | -499.48% | 6.07% | -5.28% | -229.87% | 44.99% |
| Normalized Diluted EPS | 27.58% | -4.62% | -12.15% | -34.77% | 27.40% |
| Average Basic Shares Outstanding | 27.33% | 12.30% | 8.31% | 6.46% | 3.43% |
| Average Diluted Shares Outstanding | 27.33% | 12.30% | 8.31% | 6.46% | 3.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |